CapnoXal®
Peritoneal and Pleural Cancer
UnknownActive
Key Facts
About CapnoPharm
CapnoPharm is a private, clinical-stage biotech pioneering targeted aerosol delivery for peritoneal and pleural cancers. Built on the proprietary PIPAC platform, the company is advancing lead assets CapnoDC® and CapnoXal® towards regulatory approval, combining CE-marked nebulizers with reformulated chemotherapies. With strong IP, over €28M in raised R&D funding, and recent recognition from the European Commission, CapnoPharm is positioning itself as a leader in a niche but high-need oncology segment. The company operates as a partner for pharmaceutical firms seeking to enhance existing or next-generation drugs through its specialized delivery system.
View full company profile